Chidamide and chemo for older adults with double-expressor DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years or older.
- You have been newly diagnosed with diffuse large B-cell lymphoma (DLBCL) that is CD20-positive and has high levels of MYC and BCL2 proteins (double-expressor).
- You have not received any prior treatment for DLBCL.
- You have at least one area of disease that shows up on a PET-CT scan.
- You need to be generally able to care for yourself (ECOG performance status 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a combination of three drugs for newly diagnosed older adults with a specific type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this treatment is safe and effective for patients who may not be able to tolerate standard chemotherapy.
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
This trial tests adding chidamide to standard chemotherapy (R-CHOP) for people newly diagnosed with a specific subtype of diffuse large B-cell lymphoma. It may help improve outcomes for those whose cancer cells have high levels of MYC and BCL2 proteins.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.